Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Fox Business’ Lydia HU, the latest news about the latest news from the drug industry as a drug failure reaches a new record.
Pfizer announced the development of the development of the oral weight loss pill after a patient on Monday experienced liver problems.
The company said that the investigation was investigated for Danuglipron, Oral Weight Management, and discovered that the patient’s medication was discovered that the participant was an employee’s experienced liver injury “.
Among more than 1,400 people who took the drug, the number of hepatic enzymes, was almost the same as being done with other approved drugs in the same category.
Clito Sima Sistani’s sharp speech, losing weight loss hugs
“When Danugliprron suspends, we try to bring promising new drugs to bring promising programs to bring innovative new medicines and to evaluate and develop promising programs in Pfizer, to evaluate and develop promising programs and evaluate promising programs.
The company said that Danugliprron’s second clinical development program will be presented in a scientific forum or presented in a journal in the future, although he would be presented in the journal.
Pfizer, Danugliprron said that Danugliprron has suspended Danugliprron after detection of “Potential Medication injured in one of the dose optimization research.” (Reuters / Carlo Allegri / Reuters)
The company’s decision competes with its competitors in a large lagging giant for a pharmaceutical giant. Morgan Stanley research has revalued the global market for obesity medications, and now expects between $ 105 billion and $ 144 billion in 2030. This consists of a $ 77 billion project. According to Morgan Stanley’s research in 2023, sales of branded obesity drugs are $ 6 billion.
Doctors draw attention to security issues associated with popular weight loss
The competition in the space is intensified, Novo Nordisk and Eli Lilly, to dominate the value of their value Blockbuster weight loss medications For patients who pay cash – efficient expansion for those who are insured through self-paying pharmacy programs.
Pfizer, lucrative weight loss competes with rivals with Eli Lilly and Novo Nordisk in the drug market. (Reuters / Reuters pictures via ScanPix Denmark / Liselotte Sabroe)
This is not the first decline for Pfizer to Danugliprron. The company has eliminated its development Daily Weight loss pill After a clinical test in 2023, the users showed “high degrees” of negative side effects.
At the same time, the company’s most negative events were mild and gastric and stomach-gastric-stomach-stomaca-stomacha-stomach-gastro-stomach-and-stomach-stomach-gastro-stomach-gastro-stomach-gastro-stomach, vomiting, 47%, diarrhea, diarrhea, diarrhea, diarrhea.
| Ticker | Safety | Last | Change | Change% |
|---|---|---|---|---|
| PFE | Company Name Pfizer Inc. | 21.91 | +0.32 |
+ 1.48% |
| Lly | ELI LILLY & CO. | 732.41 | +11.50 |
+ 1.60% |
| Very cite | Novo Nordisk A / S | 64.73 | +3.52 |
+ 5.75% |
Get the fox work on the way by clicking here
“High stalls have been seen in all doses compared to about 40% with more than 50%, more than 50%,” he said.
Fox’s work ‘Greg Norman contributed to this report.
